{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:52:13Z","timestamp":1793847133457,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11334-z","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T09:42:37Z","timestamp":1756633357000},"page":"3857-3880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structure-guided discovery of a novel BTK inhibitor inducing apoptosis and G1 phase arrest in tumor cells"],"prefix":"10.1007","volume":"30","author":[{"given":"Alok","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Hemalatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"11334_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"11334_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12032-024-02525-z","volume":"41","author":"A Sharma","year":"2024","unstructured":"Sharma A, Raut SS, Shukla A et al (2024) DDX3X dynamics, glioblastoma\u2019s genetic landscape, therapeutic advances, and autophagic interplay. Med Oncol 41:258. https:\/\/doi.org\/10.1007\/s12032-024-02525-z","journal-title":"Med Oncol"},{"key":"11334_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152389","volume":"52","author":"A Sharma","year":"2025","unstructured":"Sharma A, Raut SS, Shukla A et al (2025) From tissue architecture to clinical insights: spatial transcriptomics in solid tumor studies. Semin Oncol 52:152389. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152389","journal-title":"Semin Oncol"},{"key":"11334_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.transci.2013.07.014","volume":"49","author":"P Skrabek","year":"2013","unstructured":"Skrabek P, Turner D, Seftel M (2013) Epidemiology of non-Hodgkin lymphoma. Transfus Apher Sci 49:133\u2013138. https:\/\/doi.org\/10.1016\/j.transci.2013.07.014","journal-title":"Transfus Apher Sci"},{"key":"11334_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"11334_CR6","doi-asserted-by":"publisher","first-page":"41435","DOI":"10.1074\/jbc.M104828200","volume":"276","author":"C Mao","year":"2001","unstructured":"Mao C, Zhou M, Uckun FM (2001) Crystal structure of Bruton\u2019s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia*. J Biol Chem 276:41435\u201341443. https:\/\/doi.org\/10.1074\/jbc.M104828200","journal-title":"J Biol Chem"},{"key":"11334_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-981-97-6270-5_14","volume-title":"Industrial microbiology and biotechnology","author":"A Sharma","year":"2024","unstructured":"Sharma A, Raut SS, Dhikale P et al (2024) Navigating the landscape of cancer-induced thrombocytopenia: current challenges and emerging advances. In: Verma P (ed) Industrial microbiology and biotechnology. Springer Nature Singapore, Singapore, pp 435\u2013463"},{"key":"11334_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01513-y","author":"S Gupta","year":"2025","unstructured":"Gupta S, Sharma A, Shukla A et al (2025) From development to clinical success: the journey of established and next-generation BTK inhibitors. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-025-01513-y","journal-title":"Invest New Drugs"},{"key":"11334_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114232","volume":"233","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Xu Z et al (2022) Recent development of BTK-based dual inhibitors in the treatment of cancers. Eur J Med Chem 233:114232. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114232","journal-title":"Eur J Med Chem"},{"key":"11334_CR10","first-page":"67","volume-title":"B cell receptor signaling","author":"OBJ Corneth","year":"2016","unstructured":"Corneth OBJ, Klein Wolterink RGJ, Hendriks RW (2016) BTK signaling in B cell differentiation and autoimmunity. In: Kurosaki T, Wienands J (eds) B cell receptor signaling. Springer International Publishing, Cham, pp 67\u2013105"},{"key":"11334_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18:148\u2013167. https:\/\/doi.org\/10.1038\/nrc.2017.121","journal-title":"Nat Rev Cancer"},{"key":"11334_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686768","author":"M Palma","year":"2021","unstructured":"Palma M, Mulder TA, \u00d6sterborg A (2021) BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.686768","journal-title":"Front Immunol"},{"key":"11334_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686768","volume":"12","author":"M Palma","year":"2021","unstructured":"Palma M, Mulder TA, \u00d6sterborg A (2021) BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol 12:686768","journal-title":"Front Immunol"},{"key":"11334_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31:128\u2013130. https:\/\/doi.org\/10.1200\/JCO.2012.44.4281","journal-title":"J Clin Oncol"},{"key":"11334_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fonc.2019.00443","volume":"9","author":"S Crisci","year":"2019","unstructured":"Crisci S, Di Francia R, Mele S et al (2019) Overview of targeted drugs for mature B-cell non-hodgkin lymphomas. Front Oncol 9:443. https:\/\/doi.org\/10.3389\/fonc.2019.00443","journal-title":"Front Oncol"},{"key":"11334_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li S-J et al (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem 2:58\u201361. https:\/\/doi.org\/10.1002\/cmdc.200600221","journal-title":"ChemMedChem"},{"key":"11334_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/mol.116.107037","volume":"91","author":"AT Bender","year":"2017","unstructured":"Bender AT, Gardberg A, Pereira A et al (2017) Ability of Bruton\u2019s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol Pharmacol 91:208\u2013219. https:\/\/doi.org\/10.1124\/mol.116.107037","journal-title":"Mol Pharmacol"},{"key":"11334_CR18","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","volume":"11","author":"AR Johnson","year":"2016","unstructured":"Johnson AR, Kohli PB, Katewa A et al (2016) Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. ACS Chem Biol 11:2897\u20132907. https:\/\/doi.org\/10.1021\/acschembio.6b00480","journal-title":"ACS Chem Biol"},{"key":"11334_CR19","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","volume":"61","author":"JJ Crawford","year":"2018","unstructured":"Crawford JJ, Johnson AR, Misner DL et al (2018) Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development. J Med Chem 61:2227\u20132245. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01712","journal-title":"J Med Chem"},{"key":"11334_CR20","unstructured":"Lucca GVD, Shi Q, Liu C, et al (2013) Nicotinamide compounds useful as kinase modulators"},{"key":"11334_CR21","doi-asserted-by":"publisher","unstructured":"(2011) 242ND ACS NATIONAL MEETING. Chem Eng News Archive 89:77\u2013115. https:\/\/doi.org\/10.1021\/cen-v089n026.p077","DOI":"10.1021\/cen-v089n026.p077"},{"key":"11334_CR22","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M et al (2010) The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075\u201313080. https:\/\/doi.org\/10.1073\/pnas.1004594107","journal-title":"Proc Natl Acad Sci USA"},{"key":"11334_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"key":"11334_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa1509981","journal-title":"N Engl J Med"},{"key":"11334_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A et al (2014) BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28:649\u2013657. https:\/\/doi.org\/10.1038\/leu.2013.358","journal-title":"Leukemia"},{"key":"11334_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A et al (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134:1919\u20131928. https:\/\/doi.org\/10.1182\/blood.2019000840","journal-title":"Blood"},{"key":"11334_CR27","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/blood.2019002805","volume":"134","author":"IE Ahn","year":"2019","unstructured":"Ahn IE (2019) Cardiovascular adverse events of ibrutinib. Blood 134:1881\u20131882. https:\/\/doi.org\/10.1182\/blood.2019002805","journal-title":"Blood"},{"key":"11334_CR28","doi-asserted-by":"publisher","first-page":"C1231","DOI":"10.1152\/ajpcell.00040.2022","volume":"323","author":"TJ Zheng","year":"2022","unstructured":"Zheng TJ, Parra-Izquierdo I, Reitsma SE et al (2022) Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology. Am J Physiol Cell Physiol 323:C1231\u2013C1250. https:\/\/doi.org\/10.1152\/ajpcell.00040.2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"11334_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2471508","author":"A Korycka-Wo\u0142owiec","year":"2025","unstructured":"Korycka-Wo\u0142owiec A, Wo\u0142owiec D, \u0141awnicka H, Robak T (2025) Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what\u2019s best for patient quality of life? Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2025.2471508","journal-title":"Expert Opin Drug Saf"},{"key":"11334_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/ajhp\/zxad210","volume":"81","author":"K Tham","year":"2024","unstructured":"Tham K, Prelewicz S, deHoll S et al (2024) Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies. Am J Health Syst Pharm 81:112\u2013119. https:\/\/doi.org\/10.1093\/ajhp\/zxad210","journal-title":"Am J Health Syst Pharm"},{"key":"11334_CR31","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","volume":"38","author":"RL Wong","year":"2024","unstructured":"Wong RL, Choi MY, Wang H-Y, Kipps TJ (2024) Mutation in Bruton tyrosine kinase (BTK) A428D confers resistance to BTK-degrader therapy in chronic lymphocytic leukemia. Leukemia 38:1818\u20131821. https:\/\/doi.org\/10.1038\/s41375-024-02317-4","journal-title":"Leukemia"},{"key":"11334_CR32","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.053","volume":"17","author":"S Molica","year":"2025","unstructured":"Molica S, Allsup D (2025) Bruton\u2019s tyrosine kinase (BTK) mutations in chronic lymphocytic leukemia (CLL): a clinical view. Mediterr J Hematol Infect Dis 17:e2025053. https:\/\/doi.org\/10.4084\/MJHID.2025.053","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"11334_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0014-5793(04)00251-0","volume":"563","author":"V Lemaitre","year":"2004","unstructured":"Lemaitre V, Ali R, Kim CG et al (2004) Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation. FEBS Lett 563:75\u201381. https:\/\/doi.org\/10.1016\/S0014-5793(04)00251-0","journal-title":"FEBS Lett"},{"key":"11334_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/08927022.2011.579409","volume":"37","author":"J Delhommelle","year":"2011","unstructured":"Delhommelle J (2011) Recent advances in molecular simulation. Mol Simul 37:515\u2013515. https:\/\/doi.org\/10.1080\/08927022.2011.579409","journal-title":"Mol Simul"},{"key":"11334_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/08927022.2019.1643095","volume":"45","author":"J Delhommelle","year":"2019","unstructured":"Delhommelle J (2019) Recent advances in molecular simulation. Mol Simul 45:1067\u20131068. https:\/\/doi.org\/10.1080\/08927022.2019.1643095","journal-title":"Mol Simul"},{"key":"11334_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T et al (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8","journal-title":"J Comput Aided Mol Des"},{"key":"11334_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL et al (2007) Epik: a software program for pKaprediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21:681\u2013691. https:\/\/doi.org\/10.1007\/s10822-007-9133-z","journal-title":"J Comput Aided Mol Des"},{"key":"11334_CR38","unstructured":"Schr\u00f6dinger Release 2018\u20134: QikProp, Schr\u00f6dinger, LLC, New York, NY, 2020."},{"key":"11334_CR39","unstructured":"MacroModel, version 10.8, Schr\u00f6dinger, LLC, New York, NY, 2015"},{"key":"11334_CR40","unstructured":"Glide, version 6.7, Schr\u00f6dinger, LLC, New York, NY, 2015"},{"key":"11334_CR41","doi-asserted-by":"crossref","unstructured":"Bowers KJ, Chow E, Xu H, et al (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the 2006 ACM\/IEEE conference on Supercomputing. Association for Computing Machinery, New York, NY, USA, pp 84\u2013es","DOI":"10.1145\/1188455.1188544"},{"key":"11334_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","volume":"12","author":"E Harder","year":"2016","unstructured":"Harder E, Damm W, Maple J et al (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 12:281\u2013296. https:\/\/doi.org\/10.1021\/acs.jctc.5b00864","journal-title":"J Chem Theory Comput"},{"key":"11334_CR43","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1080\/07391102.2020.1777903","volume":"39","author":"A Singh","year":"2021","unstructured":"Singh A, Mishra A (2021) Leucoefdin a potential inhibitor against SARS CoV-2 Mpro. J Biomol Struct Dyn 39:4427\u20134432. https:\/\/doi.org\/10.1080\/07391102.2020.1777903","journal-title":"J Biomol Struct Dyn"},{"key":"11334_CR44","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1080\/07391102.2020.1868335","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra A, Kaur U, Singh A (2022) Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. J Biomol Struct Dyn 40:5128\u20135137. https:\/\/doi.org\/10.1080\/07391102.2020.1868335","journal-title":"J Biomol Struct Dyn"},{"key":"11334_CR45","unstructured":"Prime, version 4.0, Schr\u00f6dinger, LLC, New York, NY, 2015"},{"key":"11334_CR46","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10822-013-9660-8","volume":"27","author":"J Jakub\u00edk","year":"2013","unstructured":"Jakub\u00edk J, Rand\u00e1kov\u00e1 A, Dole\u017eal V (2013) On homology modeling of the M2 muscarinic acetylcholine receptor subtype. J Comput Aided Mol Des 27:525\u2013538. https:\/\/doi.org\/10.1007\/s10822-013-9660-8","journal-title":"J Comput Aided Mol Des"},{"key":"11334_CR47","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/prot.23106","volume":"79","author":"J Li","year":"2011","unstructured":"Li J, Abel R, Zhu K et al (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins 79:2794\u20132812. https:\/\/doi.org\/10.1002\/prot.23106","journal-title":"Proteins"},{"key":"11334_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jmgm.2013.09.005","volume":"46","author":"C Mulakala","year":"2013","unstructured":"Mulakala C, Viswanadhan VN (2013) Could MM-GBSA be accurate enough for calculation of absolute protein\/ligand binding free energies? J Mol Graph Model 46:41\u201351. https:\/\/doi.org\/10.1016\/j.jmgm.2013.09.005","journal-title":"J Mol Graph Model"},{"key":"11334_CR49","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1021\/ci300385h","volume":"52","author":"HK Srivastava","year":"2012","unstructured":"Srivastava HK, Sastry GN (2012) Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches. J Chem Inf Model 52:3088\u20133098. https:\/\/doi.org\/10.1021\/ci300385h","journal-title":"J Chem Inf Model"},{"key":"11334_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106772","volume":"113","author":"RK Singh","year":"2022","unstructured":"Singh RK, Verma PK, Kumar S et al (2022) Evidence that PKC\u03b1 inhibition in Dalton\u2019s lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis. Leuk Res 113:106772. https:\/\/doi.org\/10.1016\/j.leukres.2021.106772","journal-title":"Leuk Res"},{"key":"11334_CR51","doi-asserted-by":"publisher","first-page":"115849","DOI":"10.1016\/j.jep.2022.115849","volume":"302","author":"S Kumar","year":"2023","unstructured":"Kumar S, Verma PK, Shukla A et al (2023) Moringa oleifera L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton\u2019s lymphoma: an in vitro and in vivo study. J Ethnopharmacol 302:115849. https:\/\/doi.org\/10.1016\/j.jep.2022.115849","journal-title":"J Ethnopharmacol"},{"key":"11334_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112584","volume":"138","author":"S Kumar","year":"2024","unstructured":"Kumar S, Mohan V, Kant Singh R et al (2024) Tumor-derived Hsp70-CD14 interaction enhances the antitumor potential of cytotoxic T cells by activating tumor-associated macrophages to express CC chemokines and CD40 costimulatory molecules. Int Immunopharmacol 138:112584. https:\/\/doi.org\/10.1016\/j.intimp.2024.112584","journal-title":"Int Immunopharmacol"},{"key":"11334_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.131547","volume":"1249","author":"MK Gond","year":"2022","unstructured":"Gond MK, Shukla A, Pandey SK et al (2022) Mn(II) catalyzed synthesis of 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole: crystal structure, DFT, molecular docking, Hirshfeld surface analysis, and in vitro anticancer activity on DL cells. J Mol Struct 1249:131547. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131547","journal-title":"J Mol Struct"},{"key":"11334_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"11334_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.140114","volume":"1321","author":"SK Pandey","year":"2025","unstructured":"Pandey SK, Chaurasia R, Shukla A et al (2025) Exploring the synthesis, characterization, crystal structures, DFT calculation, hirshfeld surface analysis, and anticancer activity of Ni(II) complex of 1-(4-nitrobenzoyl)-4-phenyl-3-thiosemicarbazide. J Mol Struct 1321:140114. https:\/\/doi.org\/10.1016\/j.molstruc.2024.140114","journal-title":"J Mol Struct"},{"key":"11334_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R","volume":"31","author":"M van Engeland","year":"1998","unstructured":"van Engeland M, Nieland LJW, Ramaekers FCS et al (1998) Annexin V-Affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1\u20139. https:\/\/doi.org\/10.1002\/(SICI)1097-0320(19980101)31:1%3c1::AID-CYTO1%3e3.0.CO;2-R","journal-title":"Cytometry"},{"key":"11334_CR57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12032-025-02726-0","volume":"42","author":"A Shukla","year":"2025","unstructured":"Shukla A, Sharma A, Gupta S et al (2025) Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts. Med Oncol 42:169. https:\/\/doi.org\/10.1007\/s12032-025-02726-0","journal-title":"Med Oncol"},{"key":"11334_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF00185438","volume":"189","author":"M Pesce","year":"1994","unstructured":"Pesce M, De Felici M (1994) Apoptosis in mouse primordial germ cells: a study by transmission and scanning electron microscope. Anat Embryol 189:435\u2013440. https:\/\/doi.org\/10.1007\/BF00185438","journal-title":"Anat Embryol"},{"key":"11334_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-0716-2736-5_14","volume-title":"Cell-cycle synchronization: methods and protocols","author":"H Maadi","year":"2022","unstructured":"Maadi H, Soheilifar MH, Wang Z (2022) Analysis of cell cycle by flow cytometry. In: Wang Z (ed) Cell-cycle synchronization: methods and protocols. Springer, New York, pp 183\u2013195"},{"key":"11334_CR60","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1016\/j.bmcl.2015.07.102","volume":"25","author":"Q Liu","year":"2015","unstructured":"Liu Q, Batt DG, Lippy JS et al (2015) Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton\u2019s tyrosine kinase (BTK) and Janus kinase 2 (JAK2). Bioorg Med Chem Lett 25:4265\u20134269. https:\/\/doi.org\/10.1016\/j.bmcl.2015.07.102","journal-title":"Bioorg Med Chem Lett"},{"key":"11334_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/pro.321","volume":"19","author":"DJ Marcotte","year":"2010","unstructured":"Marcotte DJ, Liu Y-T, Arduini RM et al (2010) Structures of human Bruton\u2019s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci 19:429\u2013439. https:\/\/doi.org\/10.1002\/pro.321","journal-title":"Protein Sci"},{"key":"11334_CR62","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/jcc.21450","volume":"31","author":"CD Christ","year":"2010","unstructured":"Christ CD, Mark AE, van Gunsteren WF (2010) Basic ingredients of free energy calculations: a review. J Comput Chem 31:1569\u20131582. https:\/\/doi.org\/10.1002\/jcc.21450","journal-title":"J Comput Chem"},{"key":"11334_CR63","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1002\/1521-3773(20020802)41:15<2644::AID-ANIE2644>3.0.CO;2-O","volume":"41","author":"H Gohlke","year":"2002","unstructured":"Gohlke H, Klebe G (2002) Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed 41:2644\u20132676. https:\/\/doi.org\/10.1002\/1521-3773(20020802)41:15%3c2644::AID-ANIE2644%3e3.0.CO;2-O","journal-title":"Angew Chem Int Ed"},{"key":"11334_CR64","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/ar000033j","volume":"33","author":"PA Kollman","year":"2000","unstructured":"Kollman PA, Massova I, Reyes C et al (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889\u2013897. https:\/\/doi.org\/10.1021\/ar000033j","journal-title":"Acc Chem Res"},{"key":"11334_CR65","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev.biophys.30.1.211","volume":"30","author":"W Wang","year":"2001","unstructured":"Wang W, Donini O, Reyes CM, Kollman PA (2001) Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys 30:211\u2013243. https:\/\/doi.org\/10.1146\/annurev.biophys.30.1.211","journal-title":"Annu Rev Biophys"},{"key":"11334_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0928-0987(00)00076-2","volume":"10","author":"S Yamashita","year":"2000","unstructured":"Yamashita S, Furubayashi T, Kataoka M et al (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195\u2013204. https:\/\/doi.org\/10.1016\/S0928-0987(00)00076-2","journal-title":"Eur J Pharm Sci"},{"key":"11334_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1021\/js9803205","volume":"88","author":"JD Irvine","year":"1999","unstructured":"Irvine JD, Takahashi L, Lockhart K et al (1999) MDCK (Madin\u2013darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28\u201333. https:\/\/doi.org\/10.1021\/js9803205","journal-title":"J Pharm Sci"},{"key":"11334_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF01061687","volume":"21","author":"P Singh","year":"1993","unstructured":"Singh P, Roberts MS (1993) Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application. J Pharmacokinet Biopharm 21:337\u2013373. https:\/\/doi.org\/10.1007\/BF01061687","journal-title":"J Pharmacokinet Biopharm"},{"key":"11334_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0169-409x(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326. https:\/\/doi.org\/10.1016\/s0169-409x(00)00129-0","journal-title":"Adv Drug Deliv Rev"},{"key":"11334_CR70","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U","volume":"38","author":"SJ Teague","year":"1999","unstructured":"Teague SJ, Davis AM, Leeson PD, Oprea T (1999) The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 38:3743\u20133748. https:\/\/doi.org\/10.1002\/(SICI)1521-3773(19991216)38:24%3c3743::AID-ANIE3743%3e3.0.CO;2-U","journal-title":"Angew Chem Int Ed Engl"},{"key":"11334_CR71","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/a:1008130001697","volume":"14","author":"TI Oprea","year":"2000","unstructured":"Oprea TI (2000) Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14:251\u2013264. https:\/\/doi.org\/10.1023\/a:1008130001697","journal-title":"J Comput Aided Mol Des"},{"key":"11334_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00048059","volume":"11","author":"JA Hickman","year":"1992","unstructured":"Hickman JA (1992) Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121\u2013139. https:\/\/doi.org\/10.1007\/BF00048059","journal-title":"Cancer Metastasis Rev"},{"key":"11334_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.139426","volume":"1319","author":"R Chaurasia","year":"2025","unstructured":"Chaurasia R, Shukla A, Pandey SK et al (2025) Exploring the anticancer activity of 1-(2-methyl-3-furoyl)-4-phenyl-3-thiosemicarbazide and its Mn(II) complex: synthesis, spectral, crystal structures, and Hirshfeld surface analysis. J Mol Struct 1319:139426. https:\/\/doi.org\/10.1016\/j.molstruc.2024.139426","journal-title":"J Mol Struct"},{"key":"11334_CR74","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1021\/jp077090f","volume":"112","author":"D Banerjee","year":"2008","unstructured":"Banerjee D, Pal SK (2008) Dynamics in the DNA recognition by DAPI: exploration of the various binding modes. J Phys Chem B 112:1016\u20131021. https:\/\/doi.org\/10.1021\/jp077090f","journal-title":"J Phys Chem B"},{"key":"11334_CR75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jmi.12133","volume":"255","author":"N Atale","year":"2014","unstructured":"Atale N, Gupta S, Yadav UCS, Rani V (2014) Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J Microsc 255:7\u201319. https:\/\/doi.org\/10.1111\/jmi.12133","journal-title":"J Microsc"},{"key":"11334_CR76","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-017-0549-6","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Liu X, Hong Y et al (2017) Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res 36:96. https:\/\/doi.org\/10.1186\/s13046-017-0549-6","journal-title":"J Exp Clin Cancer Res"},{"key":"11334_CR77","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1535-7163.MCT-15-0923","volume":"15","author":"J Chen","year":"2016","unstructured":"Chen J, Kinoshita T, Sukbuntherng J et al (2016) Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther 15:2835\u20132844. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0923","journal-title":"Mol Cancer Ther"},{"key":"11334_CR78","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z et al (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res 37:1271\u20131277. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.028","journal-title":"Leuk Res"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11334-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11334-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11334-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:33:06Z","timestamp":1779535986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11334-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["11334"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11334-z","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All mice used in the experiments were procured from the animal house facility at the Institute of Medical Science, Banaras Hindu University. This study was\u00a0approved by the Institute Animal Ethics Committee (IAEC) of IIT-BHU (Varanasi, India) and the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India, New Delhi. The IAEC approval number for this study is IIT(BHU)\/IAEC\/2024\/II\/001. Additionally, this study adheres to the ARRIVE guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}